Compare Amphastar Pharmaceuticals Inc (AMPH) vs First Citizens BancShares Inc (FCNCA) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

First Citizens BancShares (FCNCA) trades at $2,092.59, up 0.46% on the day, with a bearish technical signal but bullish moving averages. The company reported strong Q1 2026 earnings of $44.86 per share, beating estimates, and maintains a net income margin of 24.35%. Recent news highlights expansion in commercial banking and a planned rebrand of Silicon Valley Bank operations. Valuation ratios include a P/E of 12.07 and P/B of 1.2, suggesting reasonable pricing relative to earnings and book value.

The outlook for FCNCA is mixed, with solid profitability and earnings beats offset by margin pressure and credit risks. Analysts are predominantly neutral (82% hold), with a consensus price target of $2,320. Key risks include deposit volatility in tech-exposed segments and competitive pressures, while opportunities lie in continued operational execution and strategic expansions.